Skip to content
Dosage GuideResearch Reference

ARA-290 Dosage

Research-based dosing protocols, timing guidance, and reconstitution reference for ARA-290. All information is for educational purposes only.

Quick Answer

In clinical trials, ARA-290 has been administered subcutaneously at 4 mg once daily for 28 days for sarcoidosis neuropathy. Intravenous infusions of 2-8 mg have been used in earlier studies. Subcutaneous dosing is preferred for chronic conditions. No dose-ranging studies exist to optimize therapeutic response.

→ ARA-290 Benefits→ ARA-290 Side Effects→ Full ARA-290 Profile
Table of Contents

Standard Dosage Range

Research dosing range: 4 mg subcutaneous once daily

Educational reference only

These dosage ranges are derived from preclinical research and community protocols. No human clinical dose-ranging trials have established therapeutic doses for most research peptides. Always consult a qualified healthcare provider before starting any peptide protocol.

Dosage by Use Case

Sarcoidosis-Associated Neuropathy

4 mg1× daily
Duration

28 days

Subcutaneous injection. Based on phase 2 clinical trial demonstrating improved nerve fiber density and reduced pain.

Diabetic Neuropathy

4 mg1× daily
Duration

4–12 weeks

Subcutaneous injection. May require longer treatment duration based on individual response and nerve regeneration rate.

Corneal Nerve Fiber Regeneration

4 mg1× daily
Duration

4 weeks

Subcutaneous injection. Studied for improving corneal nerve fiber density in small fiber neuropathy patients.

Acute Tissue Protection (experimental)

2–8 mgSingle dose
Duration

Single dose

Intravenous infusion. Used in early clinical studies; subcutaneous is preferred for chronic conditions.

Timing & Frequency

Subcutaneous injections are typically administered at the same time each day. Intravenous infusions would be administered under medical supervision as a single dose.

Cycle Guidance

Clinical trials used 28-day treatment cycles. Longer cycles (8-12 weeks) may be considered based on individual response and medical supervision. No established cycling protocol exists; monitor for therapeutic effects and potential side effects.

Reconstitution Reference

Quick reference for reconstituting ARA-290. For custom vial sizes and concentrations, use the Reconstitution Calculator.

Common Vial SizeTypically 4 mg per vial
BAC Water Volume1 mL bacteriostatic water for 4 mg/mL concentration
Concentration & DrawAt 4 mg/mL: 1 mg = 0.25 mL (25 units on a 100-unit insulin syringe)
StorageRefrigerate at 2–8°C after reconstitution. Keep lyophilized powder at room temperature or refrigerated.
StabilityReconstituted solution stable up to 14 days refrigerated. Lyophilized powder stable 12–24 months per manufacturer specifications.
Use the Reconstitution Calculator → for precise injection volumes based on your exact vial size, water volume, and desired dose.

Frequently Asked Questions

What is the standard ARA-290 dosage for neuropathy?
The most common dosage, based on phase 2 trials, is 4 mg administered subcutaneously once daily for 28 days. The optimal dosage and duration may vary based on individual condition and response.
Can ARA-290 be taken orally?
No, ARA-290 is administered via subcutaneous injection or intravenous infusion. Oral bioavailability is likely poor given its peptide structure. Injection ensures direct delivery to the bloodstream.
How do I calculate my ARA-290 injection volume?
Use our Reconstitution Calculator (/tools/reconstitution-calculator) for exact math. Quick reference: If you reconstitute 4 mg of ARA-290 in 1 mL of bacteriostatic water, you get a concentration of 4 mg/mL (4,000 mcg/mL). For a 4 mg dose: 4 mg in 1 mL, which is 100 units on a 100-unit insulin syringe.
How long does ARA-290 take to work?
Clinical trials for neuropathy showed significant improvements in nerve fiber density after 28 days of treatment. Subjective pain reduction may be noticed earlier, but nerve regeneration is a gradual process requiring consistent dosing.
Where should ARA-290 be injected?
Subcutaneous injections can be administered in the abdomen, thigh, or upper arm. Rotate injection sites to minimize irritation. Avoid injecting into areas with scar tissue or inflammation.
What is the best ARA-290 cycle length?
Clinical trials used 28-day cycles. Longer cycles (8-12 weeks) may be considered under medical supervision. No established cycling protocol exists; monitor for therapeutic effects and potential side effects.

References

  1. 1
    ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes(2012)PubMed ↗
  2. 2
    Cibinetide (ARA 290) improves small nerve fiber density and pain in sarcoidosis patients: a randomized controlled trial(2014)PubMed ↗
  3. 3
    Novel treatment of symptomatic sarcoidosis small fiber neuropathy with cibinetide(2019)PubMed ↗

Last updated: 2026-02-19